Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
A woman holds up a round hand mirror and checks her face, with a lake behind her.

Hereditary Angioedema Treatments Compared

5 FDA-approved drugs, plus 2 in development, side by side from the current prescribing labels. Newest label Aug 2026. Checked October 1, 2026.

The full Hereditary Angioedema guide, with open trials and help paying →

Prevention, injectionsTakhzyro · Andembry · Dawnzera
Prevention, daily pillOrladeyo
On-demand treatmentEkterly

Five newer drugs are FDA-approved for hereditary angioedema, and 4 of them prevent attacks while 1 treats an attack once it starts.

  • The preventives, all taken at home, are Takhzyro, an injection every 2 weeks; Orladeyo, a daily capsule; Andembry, a monthly injection; and Dawnzera, an injection every 4 or 8 weeks.
  • In their placebo-controlled trials they cut attack rates by 44% for Orladeyo and 81-89% for the 3 injections.
  • Ekterly, approved July 2025, is the first oral on-demand treatment, taken as 2 tablets at the first sign of an attack, with symptom relief in a median of 2 hours.
  • People on a preventive still carry an on-demand medicine for breakthrough attacks.

Latest for hereditary angioedema

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

Free email alert

Email me the day the FDA decides on Lonvo-z

The FDA is due to decide by March 10th. You get one email when the decision is public, plus new trials and FDA news for this condition.

You'll get trial alerts and disease updates for Hereditary Angioedema, and you can turn either off anytime. We never share your email. Privacy policy

Side by side

5 approved hereditary angioedema treatments at a glance

How each drug is given, how often, who it is approved for and when it was first approved, from the current FDA label.

Hereditary Angioedema treatments compared: route, schedule, approved use and approval date
DrugHow it is givenHow oftenApproved forFirst approved
lanadelumab-flyo
Takeda
Under-the-skin injection every 2 weeks (every 4 weeks if attack-free for 6 months), self-given from age 12300mg under the skin every 2 weeks from age 12; 300mg every 4 weeks may be considered if attack-free for more than 6 months. Ages 6 to 11: 150mg every 2 weeks; ages 2 to 5: 150mg every 4 weeksPrevention of HAE attacks in adults and children 2 and olderAugust 23, 2018
berotralstat
BioCryst
One capsule a day by mouth with food (oral pellets for ages 2 to 11)150mg capsule once daily with food from age 12; weight-based oral pellets (72 to 132mg) once daily for ages 2 to 11; 110mg if moderate or severe liver impairmentPrevention of HAE attacks in adults and children 2 and older; not for treating an attackDecember 3, 2020
garadacimab-gxii
CSL Behring
Under-the-skin injection once a month with a prefilled pen, self-given400mg loading dose (2 injections) on day 1, then 200mg under the skin once a monthPrevention of HAE attacks in adults and children 12 and olderJune 16, 2025
sebetralstat
KalVista Pharmaceuticals
2 tablets by mouth at the first sign of an attack; a second dose 3 hours later if needed600mg (2 tablets) at the earliest sign of an attack; may repeat 600mg after at least 3 hours; maximum 1,200mg in 24 hours. Dose reduced with moderate CYP3A4 inhibitors or moderate liver impairmentOn-demand treatment of acute HAE attacks in adults and children 12 and older; not a preventiveJuly 3, 2025
donidalorsen
Ionis Pharmaceuticals
Under-the-skin injection every 4 weeks (every 8 weeks is an option) with an autoinjector, self-given80mg under the skin every 4 weeks; 80mg every 8 weeks may be consideredPrevention of HAE attacks in adults and children 12 and olderAugust 21, 2025
The calendar

A year on each hereditary angioedema treatment

Every dose in a year, drawn to the label schedule, so you can see at a glance how often each one is given.

Takhzyro
Injection, at home
26 doses a year
Orladeyo
By mouth, at home
365 doses a year
Andembry
Injection, at home
12 doses a year
Ekterly
By mouth, at home
600mg (2 tablets) at the earliest sign of an attack (no fixed yearly count)
Dawnzera
Injection, at home
13 doses a year

Counts follow the label schedule for a full year on the maintenance dose. Drugs given in cycles or adjusted to blood tests have no fixed count, so their schedule is written out instead.

The evidence

What the pivotal hereditary angioedema trials showed

The primary result from the trial each FDA approval rests on, as reported on the label.

Hereditary Angioedema pivotal trial results by drug
DrugPivotal trialPrimary result
lanadelumab-flyo
Takeda
HELP (Trial 1), 125 people aged 12 and older
Trial record or paper
0.26 attacks per month on 300mg every 2 weeks vs 1.97 on placebo over 26 weeks, an 87% reduction (n=27 vs 41)
berotralstat
BioCryst
APeX-2 (Trial 1, Part 1), 120 people aged 12 and older
Trial record or paper
1.31 attacks per month on 150mg vs 2.35 on placebo over 24 weeks, a 44% reduction (n=40 vs 40)
garadacimab-gxii
CSL Behring
VANGUARD, 64 people aged 12 and older
Trial record or paper
0.22 attacks per month vs 2.07 on placebo over 6 months, an 89% reduction (n=39 vs 25); 62% were attack-free vs 0%
sebetralstat
KalVista Pharmaceuticals
KONFIDENT, 110 people aged 12 and older treating 264 attacks (crossover)
Trial record or paper
Symptom relief began in a median 2.0 hours; 76% of patients on 600mg reached relief within 12 hours vs 49% on placebo (n=93 vs 84)
donidalorsen
Ionis Pharmaceuticals
OASIS-HAE, 90 people aged 12 and older
Trial record or paper
0.44 attacks per 4 weeks on the every-4-weeks dose vs 2.26 on placebo over 24 weeks, an 81% reduction (n=45 vs 22); every 8 weeks: 55% reduction (n=23)
Safety

Hereditary Angioedema treatment side effects and warnings

None of these drugs carries a boxed warning. Each label's main precautions are listed. Side effect rates show how many people in each drug's trials reported each one, whether or not the drug caused it.

Hereditary Angioedema treatments: most common side effects and key warnings from the FDA labels
DrugMost common side effectsKey warning
lanadelumab-flyo
Takeda
injection site reactions 52%, upper respiratory infection 29% and headache 21%No boxed warning. Hypersensitivity reactions.
berotralstat
BioCryst
abdominal pain 23%, vomiting 15% and diarrhea 15%No boxed warning. QTc prolongation (heart rhythm) at doses above the recommended dose; never take extra doses or use it for an acute attack.
garadacimab-gxii
CSL Behring
common cold symptoms 21%, injection site reactions 14% and abdominal pain 8%No boxed warning and no Warnings and Precautions listed on the label. Prolonged clotting tests (aPTT, PT) seen in some patients without bleeding.
sebetralstat
KalVista Pharmaceuticals
headache 3.2%No boxed warning and no Warnings and Precautions section. Avoid with strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers, and severe liver impairment.
donidalorsen
Ionis Pharmaceuticals
injection site reactions 24%, upper respiratory tract infection 9% and urinary tract infection 9%No boxed warning. Hypersensitivity reactions including anaphylaxis; platelet count decreases.
Not yet approved

Hereditary angioedema treatments in Phase 3 or under FDA review

Investigational drugs with a Phase 3 trial, shown separately because their results are not from a label. Status as of the date in each row.

Hereditary Angioedema drugs not FDA-approved
DrugStatusHow it works and is givenPivotal trialResult so farWhat is next
Intellia Therapeutics
Under FDA reviewas of November 7, 2026One-time CRISPR gene edit in the liver that switches off KLKB1, the gene for prekallikreinSingle 50mg IV infusion, given onceHAELO, Phase 3, 80 people aged 16 and olderPrimary endpoint: Monthly HAE attack rate, weeks 5 to 28
ClinicalTrials.gov
Met primary endpoint: 0.26 attacks a month on lonvo-z vs 2.10 on placebo, 87% lower (Cohn et al., New England Journal of Medicine, 2026)FDA target action date March 10, 2027 (Priority Review); for prevention of attacks in HAE type 1 or 2, age 16 and older
Intellia press release, September 8, 2026
Pharvaris
Under FDA reviewas of November 7, 2026Oral blocker of the bradykinin B2 receptor, the same target as icatibant20mg capsule by mouth, taken when an attack startsRAPIDe-3, Phase 3, 134 people aged 12 to 75Primary endpoint: Time to the start of symptom relief after treating an attack
ClinicalTrials.gov
Met primary endpoint: median 1.28 hours on deucrictibant vs more than 12 hours on placebo (Riedl et al., The Lancet, 2026)FDA target action date April 23, 2027, for the on-demand capsule only; the once-daily prevention tablet is not part of this review
Pharvaris press release, July 6, 2026
Cost

Help paying for hereditary angioedema treatment

Drugmaker copay and free-drug programs, plus charity funds for the condition, checked every week.

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read
Follow Hereditary Angioedema treatment news by email

One email when the FDA acts on a Hereditary Angioedema treatment, a label changes or a new trial opens. Never a newsletter.

You'll get, for Hereditary Angioedema:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Questions

Hereditary Angioedema treatment questions people ask

What is the best preventive treatment for hereditary angioedema?

No trial has compared the 4 preventives. Against placebo, Andembry cut monthly attacks by 89%, Takhzyro by 87%, Dawnzera by 81% and Orladeyo by 44%, in separate trials with different designs. The practical choices are a daily capsule (Orladeyo) against an injection every 2 weeks (Takhzyro), 4 weeks (Andembry and Dawnzera) or 8 weeks (Dawnzera, in some patients), and which ages each covers.

Is there a pill to prevent hereditary angioedema attacks?

Yes. Orladeyo (berotralstat) is 1 capsule a day with food from age 12, with oral pellets for ages 2 to 11. In its trial it reduced attacks by 44% against placebo, less than the injected preventives, which were 81-89% in their own trials.

What is Ekterly used for?

Ekterly (sebetralstat) is taken when an attack starts: 2 tablets at the first sign, with a second dose 3 hours later if needed, for people 12 and older. In its trial, 76% reached symptom relief within 12 hours against 49% on placebo, with a median time to relief of 2 hours. It is the first oral on-demand HAE treatment and is not for prevention.

Which HAE preventive is given least often?

Dawnzera (donidalorsen), which is injected every 4 weeks and can be moved to every 8 weeks in patients who do well; Andembry is monthly. Takhzyro starts at every 2 weeks and can move to every 4 weeks after 6 attack-free months. Orladeyo is daily.

Which HAE treatments are under FDA review?

The FDA is reviewing 2. Deucrictibant from Pharvaris is a capsule taken by mouth when an attack starts, for people 12 and older, with an FDA decision date of April 23, 2027. In its RAPIDe-3 trial, symptom relief began in a median of 1.28 hours, according to Pharvaris. Lonvo-z (lonvoguran ziclumeran) from Intellia is a one-time infusion that uses CRISPR gene editing, with an FDA decision date of March 10, 2027. Neither is approved yet.

Go deeper

More on Hereditary Angioedema at Trial Friend

Sources

Where every number on this page comes from

Approved-drug facts are from the current FDA prescribing information on DailyMed or the FDA's own site, with the label's effective date. Investigational-drug facts are from ClinicalTrials.gov and the sources named in each row.

  1. Takhzyro (lanadelumab-flyo) prescribing information, Takeda, label dated Aug 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  2. Orladeyo (berotralstat) prescribing information, BioCryst, label dated Aug 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  3. Andembry (garadacimab-gxii) prescribing information, CSL Behring, label dated Jun 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
  4. Ekterly (sebetralstat) prescribing information, KalVista Pharmaceuticals, label dated Apr 2026. DailyMed. Pivotal trial: ClinicalTrials.gov
  5. Dawnzera (donidalorsen) prescribing information, Ionis Pharmaceuticals, label dated Sep 2025. DailyMed. Pivotal trial: ClinicalTrials.gov
  6. lonvo-z (lonvoguran ziclumeran), Intellia Therapeutics: ClinicalTrials.gov record; Intellia press release, September 8, 2026. Checked November 7, 2026.
  7. deucrictibant, Pharvaris: ClinicalTrials.gov record; Pharvaris press release, July 6, 2026. Checked November 7, 2026.

This page compares what the FDA labels and pivotal trials report. It is not medical advice, and no trial on this page compared these drugs with each other. Written and checked by Jason Hunter; the method is on the editorial standards page.